Abstract
Addition of carboplatin (CBDCA) to neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) has improved pathological complete response (pCR) rates in previous studies. We present long-term survival outcomes (disease-free survival [DFS], pre-planned secondary endpoint; overall survival [OS], post hoc exploratory endpoint) of our randomized study of the addition of CBDCA to NAC for HER2-negative breast cancer. Patients with stage II/III, HER2-negative breast cancer (N = 179) were randomly assigned to receive CP-CEF (four 3-week cycles of CBDCA [area under the curve, 5 mg/mL/min, day 1] and weekly paclitaxel [wPTX, 80 mg/m2, day 1, 8, 15] followed by four 3-week cycles of cyclophosphamide, epirubicin, and 5-fluorouracil [CEF, 500/100/500 mg/m2]) or P-CEF (four cycles of wPTX followed by four cycles of CEF) as NAC. DFS and OS were analyzed at each population of pCR status and assigned treatment arm. Of 179 patients, 154 were available for long-term follow-up. At a median follow-up of 6.6 years (range, 0.7-8.0 years), patients who achieved pCR [n = 42, 23.5% (CP-CEF: n = 28, P-CEF: n = 16)] had longer DFS and OS than non-pCR patients [DFS; HR 0.15 (0.04-0.61), P = 0.008, OS; log-rank P = 0.003]. Addition of carboplati...Continue Reading
References
Feb 6, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cornelia LiedtkeLajos Pusztai
Apr 18, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gunter von MinckwitzSibylle Loibl
Jul 7, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Nehmat HoussamiEleftherios Mamounas
Feb 18, 2014·Lancet·Patricia CortazarGunter von Minckwitz
Mar 13, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H BonnefoiUNKNOWN EORTC 10994/BIG 1-00 Study investigators
Apr 15, 2014·Breast Cancer Research and Treatment·Masashi AndoYasuhiro Fujiwara
May 6, 2014·The Lancet Oncology·Gunter von MinckwitzMichael Untch
Aug 6, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William M SikovEric P Winer
Aug 19, 2014·Breast Cancer Research and Treatment·T ByrskiS A Narod
Mar 10, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Melinda L TelliAndrea L Richardson
Jun 17, 2016·PloS One·Brian D LehmannJennifer A Pietenpol
Jul 15, 2016·The New England Journal of Medicine·Hope S RugoUNKNOWN I-SPY 2 Investigators
Jan 31, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W Fraser SymmansGabriel N Hortobagyi
Jul 18, 2017·JAMA Oncology·Eric HahnenRita K Schmutzler
Mar 5, 2018·The Lancet Oncology·Sibylle LoiblCharles E Geyer
Oct 20, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S LoiblM Untch
Citations
Feb 6, 2021·Scientific Reports·Stijn MoensFrédéric Amant
Jul 24, 2021·Journal of Experimental & Clinical Cancer Research : CR·Lisa AgnelloLaura Cerchia
Aug 10, 2021·Frontiers in Oncology·Willy Antoni Abreu de OliveiraFrederic Lluis